Platelet effects of a cholesterol-lowering enzyme
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how a natural enzyme in the body, called PCSK9, affects blood platelets. It compares healthy people to those with heart risk factors to see if the enzyme changes how platelets work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 50 years old
- You are either healthy or have at least 3 heart risk factors (such as high cholesterol, high blood pressure, overweight, smoking, prediabetes/diabetes, or family history of heart disease)
- You cannot be taking certain diabetes medications (like GLP-1 agonists or SGLT2 inhibitors) or high-dose statins or PCSK9 inhibitors
- You cannot have had a heart attack or stroke, or have used blood thinners or antiplatelet drugs in the past 14 days
- You cannot have certain medical conditions like kidney disease, liver disease, HIV, hepatitis, active cancer, or be pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
This study tests an educational program to help people understand and lower their LDL ('bad') cholesterol after a heart-related event. It aims to improve awareness and encourage the use of cholesterol-lowering treatments.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
Hear when a new Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.